News >

Emerging TNBC Agents Show Improved Patient Outcomes

Jessica Hergert
Published: Thursday, Sep 19, 2019

Sylvia Adams, MD

Sylvia Adams, MD
The metastatic triple-negative breast cancer (TNBC) space, which typically has a short survival prognosis, is advancing through the introduction of novel treatment strategies, involving antibody-drug conjugates, PARP inhibitors, and immunotherapy, said Sylvia Adams, MD.

"The landscape is very much changing in TNBC," said Adams. "Up until 1 or 2 years ago, we only had chemotherapy. With that, the outcomes were dismal with, 1 year, or maybe one and a half years, for survival; but now we have new agents."

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication